Emerging Treatment Options for Recurrent C. Difficile Infection

A gastroenterologist, Dr. Paul Feuerstadt, provides an overview of C. difficile infection (CDI) and vegetative and spore phases of CDI.

Drs Lodise and Feuerstadt discuss risk factors for C. difficile infection (CDI).

Drs. Abraham, Chopra and Feuerstadt discuss importance of timely referral and diagnostic methods to discern C. difficile infection (CDI).

Dr. Chopra shares multipronged approach to reducing C. difficile infection (CDI) and the role of antimicrobial stewardship.

Drs. Lodise and Feuerstadt discuss educational opportunities to combat and reduce C. difficile infection (CDI).

A gastroenterologist, Dr. Bincy Abraham, provides an overview of C. difficile infection (CDI) in patients with inflammatory bowel disease (IBD).

Dr. Abraham discusses importance of differential diagnosis of C. difficile infection (CDI) in patients with IBD and how both IBD and CDI should be managed.

Dr. Tom Lodise provides an overview of gut microbiota and the consequences of dysbiosis.

A gastroenterologist reviews long-term impact of dysbiosis and C. difficile infection (CDI).

Experts review treatment options for first, second and recurring episodes of Clostridioides difficile infection.

Drs Tom Lodise and Bincy Abraham provide an overview of fecal microbiota transplantation and long-term safety of FMT use.

Dr Teena Chopra shares her approach to monitoring patients with C difficile infection (CDI).

Dr Lodise summarizes foundational trials that led to the use of fecal microbiota transplant for the treatment of rCDI.

Drs Chopra and Feuerstadt summarize challenges with current treatments and discuss live biotherapeutic products that are being studied for recurrent C difficile infection (rCDI).

Drs Feuerstadt, Abraham, and Chopra discuss clinical trial data for RBX2660, a live biotherapeutic product, in treatment of recurrent C difficile infection (rCDI), as well as data with RBX2660 that were presented at DDW 2022.

Drs Abraham and Feuerstadt share recent data with emerging live biotherapeutic products, SER-109, CP101, and VE303, for treatment of recurrent C difficile infection (rCDI).

Experts discuss differences in designs of clinical trials of 4 emerging microbiota-based live biotherapeutics - RBX2660, SER-109, CP101, VE303, for treatment of rCDI.

Bincy Abraham, MD, MS; Thomas Lodise, PharmD, PhD; Teena Chopra, MD, MPH; and Paul Feuerstadt, MD, share unmet needs, including access to therapies, in treatment of C. difficile infection (CDI).

Experts share advice for physicians taking care of patients with C. difficile infection (CDI).